Bionano Announces Publication Outlining Utility of OGM for Resolution of MYC Gene Rearrangements in Multiple Myeloma
Bionano Genomics (BNGO) announced a publication in Blood Cancer Journal highlighting the effectiveness of Optical Genome Mapping (OGM) in detecting MYC gene rearrangements in multiple myeloma (MM). The study, conducted by researchers at Korea College of Medicine, demonstrated that OGM identified MYC-positive cases in 40% of samples, compared to 26% with FISH and 13% with karyotype methods. The research emphasizes OGM's superior ability to resolve translocation partners and provide comprehensive genome variation analysis, potentially streamlining workflow and improving cost efficiency in MM diagnosis and research.
Bionano Genomics (BNGO) ha annunciato una pubblicazione su Blood Cancer Journal che evidenzia l'efficacia del Mapping Ottico del Genoma (OGM) nella rilevazione delle riarrangiamenti del gene MYC nel mieloma multiplo (MM). Lo studio, condotto dai ricercatori del Korea College of Medicine, ha dimostrato che l'OGM ha identificato casi positivi per MYC nel 40% dei campioni, rispetto al 26% con il metodo FISH e al 13% con i metodi di cariotipizzazione. La ricerca sottolinea la superiore capacità dell'OGM di risolvere i partner di traslocazione e fornire un'analisi completa delle variazioni genomiche, con il potenziale di snellire il flusso di lavoro e migliorare l'efficienza dei costi nella diagnosi e ricerca del MM.
Bionano Genomics (BNGO) anunció una publicación en Blood Cancer Journal que destaca la efectividad del mapeo óptico del genoma (OGM) en la detección de reordenamientos del gen MYC en mieloma múltiple (MM). El estudio, realizado por investigadores del Korea College of Medicine, demostró que el OGM identificó casos positivos para MYC en el 40% de las muestras, en comparación con el 26% con el método FISH y el 13% con métodos de cariotipificación. La investigación enfatiza la superior capacidad del OGM para resolver socios de translocación y proporcionar un análisis integral de la variación genética, lo que potencialmente puede agilizar el flujo de trabajo y mejorar la eficiencia de costos en el diagnóstico e investigación del MM.
Bionano Genomics (BNGO)는 Blood Cancer Journal에 발표를 하였으며, 이는 광학 유전체 맵핑(OGM)이 다발성 골수종(MM)에서 MYC 유전자 재배열을 감지하는 데 효과적임을 강조하고 있습니다. 한국 의대의 연구자들이 수행한 이 연구에서는 OGM이 40%의 샘플에서 MYC 양성 사례를 식별하였으며, FISH 방법에서는 26%, 염색체 배열법에서는 13%로 나타났습니다. 이 연구는 OGM의 전이 협력자를 해결하고 포괄적인 유전체 변이 분석을 제공하는 능력이 우수함을 강조하며, MM 진단 및 연구에서 업무 흐름을 간소화하고 비용 효율성을 개선할 수 있는 가능성을 제시합니다.
Bionano Genomics (BNGO) a annoncé une publication dans Blood Cancer Journal soulignant l'efficacité de la cartographie optique du génome (OGM) dans la détection des réarrangements du gène MYC dans le myélome multiple (MM). L'étude, menée par des chercheurs du Korea College of Medicine, a démontré que l'OGM identifiait des cas positifs pour MYC dans 40% des échantillons, contre 26% avec la méthode FISH et 13% avec les méthodes de caryotype. La recherche souligne la capacité supérieure de l'OGM à résoudre des partenaires de translocation et à fournir une analyse complète des variations génomiques, ce qui pourrait rationaliser le flux de travail et améliorer l'efficacité des coûts dans le diagnostic et la recherche du MM.
Bionano Genomics (BNGO) gab eine Veröffentlichung im Blood Cancer Journal bekannt, die die Wirksamkeit der optischen Genomkartierung (OGM) bei der Erkennung von MYC-Genumstellungen im multiplen Myelom (MM) hervorhebt. Die Studie, die von Forschern am Korea College of Medicine durchgeführt wurde, zeigte, dass OGM in 40% der Proben MYC-positive Fälle identifizierte, während es bei der FISH-Methode 26% und bei der Karyotypisierung 13% waren. Die Forschung betont die überlegene Fähigkeit von OGM, Translokationspartner zu identifizieren und eine umfassende Analyse der genomischen Variationen bereitzustellen, was möglicherweise den Arbeitsablauf optimiert und die Kosteneffizienz bei der Diagnose und Forschung von MM verbessert.
- OGM showed superior detection rate (40%) compared to traditional methods (FISH 26%, karyotype 13%)
- Technology demonstrates potential for streamlined workflow and cost efficiency by replacing multiple sequential analyses with a single assay
- OGM provides more comprehensive genome variation analysis than traditional methods
- None.
Insights
This publication demonstrates significant clinical validation for Bionano's OGM technology in multiple myeloma diagnostics. The study's findings that OGM detected
The operational efficiency highlighted - consolidating multiple sequential tests into a single assay - presents a compelling economic case for clinical adoption. However, the small market cap of
- Publication shows that OGM can resolve translocation partners involving MYC in multiple myeloma (MM) more effectively than current methods
- The release of compelling data in MM underscores the potential for wider adoption and use of OGM across all blood cancers as an alternative to traditional methods like karyotyping and fluorescence in-situ hybridization (FISH)
SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication in Blood Cancer Journal by a group of researchers at the Korea College of Medicine in South Korea showing that optical genome mapping (OGM) can resolve rearrangements in the MYC gene in multiple myeloma (MM), which represent highly actionable biomarkers in cancer. MM accounts for
Key findings:
- OGM performed better than conventional cytogenetics: Using OGM, the results were MYC-positive in
40% of cases, while positive rate was26% and13% using FISH and karyotype, respectively. Karyotyping can fail to identify MYC rearrangements and cannot resolve its translocation partners, which is a critical component in the stratification of the disease for prognosis and management. - Complementary to other molecular techniques: OGM provides a complementary approach by revealing large structural variations that may be missed by methods like next-generation sequencing (NGS). A comprehensive view of genome variation can provide a more complete understanding of the drivers of multiple myeloma, which could lead to advancements of precision medicine.
- Streamlined Workflow and Cost Efficiency: The study also highlights the efficiency of OGM compared to traditional cytogenetics, which can be time consuming and laborious. OGM can reduce the need for sequential analysis such as karyotyping, followed by multiple rounds of FISH analysis. OGM can provide the same information and more in a single assay versus the tiered assays (common in cytogenetics today), and shorten the time to accurate classification and stratification of blood cancers, including MM.
Erik Holmlin, president and chief executive officer of Bionano commented, “multiple myeloma is a devastating disease that is virtually uncurable. With proper stratification of blood cancers using OGM, we believe identification of multiple myeloma will improve and will have the potential to provide clinicians and researchers with a better understanding of the disease. This paper represents an important step in the progression of showing the utility of OGM across a wider spectrum of blood cancers and therefore increasing potential for adoption and utilization as an alternative to traditional cytogenetic methods.”
The full research publication is available at: https://rdcu.be/dXUKf
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.
For more information, visit www.bionano.com or www.bionanolaboratories.com.
Except as specifically noted otherwise, Bionano’s products are for research use only and not for use in diagnostic procedures.
Forward-Looking Statements of Bionano Genomics
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “can,” “believe,” “may,” “potential,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, OGM’s ability to resolve rearrangements in the MYC gene in MM; the potential for wider adoption and use of OGM across all blood cancers as an alternative to traditional methods like karyotyping and fluorescence in-situ hybridization (FISH); OGM’s ability to identity MYC rearrangements and resolve its translocation partners that traditional cytogenetic methods may miss; the ability of OGM to provide a complementary approach by revealing large structural variations missed by methods like NGS; OGM’s ability to provide a comprehensive view of genome variation and provide a more complete understanding of the drivers of multiple myeloma and lead to advancements of precision medicine; OGM’s ability to reduce the need for sequential analysis such as karyotyping, followed by multiple rounds of FISH analysis; OGM’s ability to provide the same information and more in a single assay versus the tiered assays (common in cytogenetics today), and to shorten the time to accurate classification and stratification of blood cancers, including MM; OGM’s ability to improve identification of MM and to provide clinicians and researchers with a better understanding of the disease; OGM’s ability and utility for adoption across a wider spectrum of blood cancers and increase in adoption and utilization as an alternative to traditional cytogenetic methods; the utility of OGM for applications in areas reported in this press release; the growth and adoption of OGM for use in hematologic research applications; and other statements that are not historical facts. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: global and macroeconomic events, such as recent and potential bank failures, supply chain disruptions, global pandemics, inflation, and the ongoing conflicts between Ukraine and Russian and Israel and Hamas, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; the failure of OGM to resolve rearrangements in the MYC gene in MM; the failure of wider adoption and use of OGM across all blood cancers as an alternative to traditional methods like karyotyping and fluorescence in-situ hybridization (FISH); the failure of OGM to identity MYC rearrangements and resolve its translocation partners that traditional cytogenetic methods may miss; the failure of OGM to provide a complementary approach by revealing large structural variations missed by methods like NGS; the failure of OGM to provide a comprehensive view of genome variation and a more complete understanding of the drivers of multiple myeloma leading to advancements of precision medicine; the failure of OGM to reduce the need for sequential analysis such as karyotyping, followed by multiple rounds of FISH analysis; the failure of OGM to provide the same information and more in a single assay versus the tiered assays (common in cytogenetics today), and to shorten the time to accurate classification and stratification of blood cancers, including MM; the failure of OGM to improve identification of MM and to provide clinicians and researchers with a better understanding of the disease; the failure of OGM to be adopted and prove useful across a wider spectrum of blood cancers and increase in adoption and utilization as an alternative to traditional cytogenetic methods; the failure of OGM to prove useful for applications in areas reported in publication referenced in this press release; future publications that contradict the findings of the publication referenced in this press release; the failure of OGM adoption to grow in hematologic research applications; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; our ability to effectively manage our uses of cash, and our ability to continue as a “going concern”; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2023 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com
Investor Relations:
David Holmes
Gilmartin Group
+1 (858) 888-7625
IR@bionano.com
FAQ
What detection rate did Bionano's OGM achieve for MYC gene rearrangements in multiple myeloma?
How does Bionano's OGM improve workflow efficiency in multiple myeloma testing?
What advantages does BNGO's OGM technology offer over traditional cytogenetic methods?
